Forty-four pts entered this non-randomized phase II study. The pts were treated with TXL (3-hour iv infusion) 175 mg/m 2 as second- (n = 23) or third-line (n = 13) chemotherapy or with TXL 135 mg/m 2 as fourth-line chemotherapy (n = 8). Standard premedication was required. All the pts are evaluable for toxicity and 35 are evaluable for objective response. An objective remission was observed in 17 (16 PR + 1 CR)/34 evaluable pts (50%). The median TTP was 28 weeks. The hematological toxicity was mild: grade 3 leukopenia in 8/44 pts (18%); gr. 3 alopecia was universal. Gr. 2–3 paresthesias were observed in 20 pts (45%), while treatment-related pain (abdominal pain, arthralgia, myalgia) was observed in 25 pts (57%). Hypersensitivity reactions occurred in 12 pts (27%); in 2 cases (4%) the reaction was severe (gr. 3 and 4). Partial bowel obstruction occurred within 30 days from TXL administration in 6 pts (14%): the relationship with chemotherapy was uncertain. Overall 8 pts (18%) stopped TXL treatment because of adverse events: 5 hypersensitivity reactions, gr. 3 paresthesias in one case, partial bowel obstruction in 2 cases. In our opinion pts with constipation or bowel subobstructive condition at the beginning of TXL treatment should be carefully selected and monitored.